SeekingAlpha · Aug 7, 2026
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)
Viking Therapeutics stock holds as GLP-1 obesity drug competition heats up. Read the latest analysis on earnings here.
VK
NASDAQ · VKTX
Viking Therapeutics, Inc.
Healthcare · Biotechnology
$32.94
Up+$0.25 (+0.76%)
Updated Aug 15, 2026, 1:35 AM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.21B
- P/E ratio
- -17.61
- Dividend yield
- 0.00%
- 52-week range
- $27.16 – $42.79
- Volume
- 3.71M
- Avg. volume
- 4.44M
Price performance
VKTX price history
1M range · 20 trading sessions · Daily adjusted prices
VKTX closed at $32.94 after 20 trading sessions, down 11.17% for the selected period.
- Last close
- $32.94
- Period change
- -11.17%
- Period low
- $31.74
- Period high
- $37.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $33.86 | $33.9712 | $32.53 | $32.94 | 3.71M |
| Aug 12, 2026 | $34.07 | $34.735 | $33.50 | $34.02 | 1.47M |
| Aug 11, 2026 | $34.71 | $34.85 | $33.62 | $33.80 | 1.01M |
| Aug 10, 2026 | $33.93 | $34.7032 | $33.8001 | $34.44 | 1.62M |
| Aug 7, 2026 | $33.82 | $34.33 | $33.21 | $34.26 | 1.4M |
| Aug 6, 2026 | $33.50 | $34.20 | $33.10 | $33.30 | 1.3M |
| Aug 5, 2026 | $33.19 | $34.08 | $32.9603 | $33.51 | 1.96M |
| Aug 4, 2026 | $32.95 | $33.62 | $32.5808 | $32.94 | 1.7M |
| Aug 3, 2026 | $31.68 | $32.73 | $31.28 | $32.61 | 1.6M |
| Jul 31, 2026 | $33.40 | $33.7499 | $31.48 | $31.74 | 1.87M |
| Jul 30, 2026 | $33.52 | $33.61 | $30.80 | $33.11 | 3.5M |
| Jul 29, 2026 | $33.86 | $34.01 | $32.84 | $33.43 | 2.9M |
| Jul 28, 2026 | $34.67 | $34.8104 | $32.72 | $33.86 | 2.33M |
| Jul 27, 2026 | $35.41 | $36.12 | $34.64 | $34.87 | 1.89M |
| Jul 24, 2026 | $35.54 | $35.77 | $34.39 | $34.79 | 1.84M |
| Jul 23, 2026 | $36.65 | $36.81 | $35.36 | $35.39 | 3.25M |
| Jul 22, 2026 | $37.67 | $38.16 | $37.05 | $37.31 | 1.35M |
| Jul 21, 2026 | $36.29 | $38.08 | $36.0212 | $37.95 | 1.79M |
| Jul 20, 2026 | $37.19 | $38.0999 | $36.36 | $36.38 | 1.91M |
| Jul 17, 2026 | $35.79 | $37.63 | $35.29 | $37.08 | 1.92M |
Latest VKTX news
The latest Smart Investors Daily articles mentioning VKTX.
Stock researchCompany · Overview
VKTX research
Overview
Company profile and research snapshot.
Company profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $104.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| May 28, 2026 | Lake Street | Buy | — |
| Apr 30, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 6, 2026
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
In a slow news month for the company, investors focused on the cost of its phase 3 trials rather than their benefits.
Yahoo · Aug 4, 2026
Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?
Why Viking Therapeutics' VK2735 News Matters For Investors Viking Therapeutics (VKTX) has drawn fresh attention after commentary on its VK2735 drug candidate highlighted the potential appeal of less frequent injections and the possibility of use in combination maintenance therapy for weight loss and metabolic disorders. See our latest analysis for Viking Therapeutics. For context, Viking Therapeutics' share price is US$32.61 after a 1 day share price return of 2.74%. However, the 30 day share...
Yahoo · Aug 4, 2026
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why
In late July 2026, Viking Therapeutics reported Q2 and first-half net losses of US$128.02 million and US$286.35 million respectively, while also filing a US$500 million at-the-market equity offering and an omnibus shelf registration covering multiple securities types. Despite these wider losses and fresh financing capacity, attention has increasingly centered on obesity candidate VK2735, whose potential for less frequent dosing and combination use has drawn industry interest and helped frame...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
